David Amsellem
Stock Analyst at Piper Sandler
(4.81)
# 73
Out of 5,072 analysts
163
Total ratings
65.89%
Success rate
25.55%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $4.01 | +124.44% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $182.09 | -13.78% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $345.46 | +10.29% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $6.19 | +29.24% | 2 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Neutral | $6 → $8 | $7.18 | +11.42% | 6 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $227.70 | +26.92% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $33.60 | +22.02% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $12.52 | +3.83% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $152.16 | +17.64% | 12 | Oct 29, 2025 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $45 | $29.58 | +52.13% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $45.59 | +42.58% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $27.72 | -9.81% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $79.40 | +52.39% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.71 | +133.46% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $46.68 | -20.74% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $176 → $147 | $176.53 | -16.73% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $49.20 | +32.11% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.69 | -6.45% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $26.89 | +11.57% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.49 | -39.51% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $84.79 | -19.80% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.35 | -52.76% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.68 | +77.36% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.50 | +500.00% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $151.50 | -25.41% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $35.29 | +19.01% | 3 | Oct 16, 2023 |
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $4.01
Upside: +124.44%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $182.09
Upside: -13.78%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $345.46
Upside: +10.29%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $6.19
Upside: +29.24%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $7.18
Upside: +11.42%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $227.70
Upside: +26.92%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $33.60
Upside: +22.02%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.52
Upside: +3.83%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $152.16
Upside: +17.64%
Alkermes
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $29.58
Upside: +52.13%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $45.59
Upside: +42.58%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $27.72
Upside: -9.81%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $79.40
Upside: +52.39%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.71
Upside: +133.46%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $46.68
Upside: -20.74%
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $176.53
Upside: -16.73%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $49.20
Upside: +32.11%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.69
Upside: -6.45%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $26.89
Upside: +11.57%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.49
Upside: -39.51%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $84.79
Upside: -19.80%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.35
Upside: -52.76%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.68
Upside: +77.36%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.50
Upside: +500.00%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $151.50
Upside: -25.41%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $35.29
Upside: +19.01%